Tamibarotene (SY-1425)

About Syros Pharmaceuticals

Syros Pharmaceuticals' mission is to develop breakthrough medicines for cancer and other diseases by controlling the expression of disease-driving genes, a historically 'undruggable' target class. Its key achievement is building a proprietary gene control platform and advancing multiple candidates into clinical trials, most notably tamibarotene for RARA-positive higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). The company's strategy hinges on clinically validating its platform to unlock the therapeutic potential of modulating transcription factors, though its path is fraught with financial and clinical execution risks. Syros's future depends on demonstrating compelling efficacy and safety data to attract partnership capital or secure alternative funding.

About Syros Pharmaceuticals

Syros Pharmaceuticals' mission is to develop breakthrough medicines for cancer and other diseases by controlling the expression of disease-driving genes, a historically 'undruggable' target class. Its key achievement is building a proprietary gene control platform and advancing multiple candidates into clinical trials, most notably tamibarotene for RARA-positive higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). The company's strategy hinges on clinically validating its platform to unlock the therapeutic potential of modulating transcription factors, though its path is fraught with financial and clinical execution risks. Syros's future depends on demonstrating compelling efficacy and safety data to attract partnership capital or secure alternative funding.

Therapeutic Areas